CYBB and metabolic dysfunction-associated steatohepatitis: Changes in hepatic content of these metabolites are associated with a corresponding decline in the NASH gene expression markers, i.e., MCP1, CD68, ProCOL1A1, NOX2, SCD1 and TLR4.